Barge Men's Beds Smell of Lavender Elixir and Red China Silk
In: The Massachusetts review: MR ; a quarterly of literature, the arts and public affairs, Band 48, Heft 1, S. 115-117
ISSN: 0025-4878
18 Ergebnisse
Sortierung:
In: The Massachusetts review: MR ; a quarterly of literature, the arts and public affairs, Band 48, Heft 1, S. 115-117
ISSN: 0025-4878
In: Bulletin of the World Health Organization: the international journal of public health, Band 83, Heft 6
ISSN: 0042-9686, 0366-4996, 0510-8659
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 2011-2019
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 1993-2009
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 1993
ISSN: 0305-750X
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 2011
ISSN: 0305-750X
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 1977
ISSN: 0305-750X
In: Reproductive Health Matters, Band 17, Heft 33, S. 120-132
SSRN
In: World development: the multi-disciplinary international journal devoted to the study and promotion of world development, Band 27, Heft 11, S. 1977-1991
In: Evaluation and program planning: an international journal, Band 56, S. 11-22
ISSN: 1873-7870
In: Development in practice, Band 31, Heft 5, S. 592-605
ISSN: 1364-9213
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 91, Heft 8, S. 585-592
ISSN: 1564-0604
In: Bulletin of the World Health Organization: the international journal of public health, Band 91, Heft 8
ISSN: 0042-9686, 0366-4996, 0510-8659
In: Journal of the International AIDS Society, Band 13, Heft 1, S. 43-43
ISSN: 1758-2652
BackgroundHIV viral load testing as a component of antiretroviral therapy monitoring is costly. Understanding the full costs and the major sources of inefficiency associated with viral load testing is critical for optimizing the systems and technologies that support the testing process. The objective of our study was to estimate the costs associated with viral load testing performed for antiretroviral therapy monitoring to both patients and the public healthcare system in a low‐HIV prevalence, low‐resource country.MethodsA detailed cost analysis was performed to understand the costs involved in each step of performing a viral load test in Nicaragua, from initial specimen collection to communication of the test results to each patient's healthcare provider. Data were compiled and cross referenced from multiple information sources: laboratory records, regional surveillance centre records, and scheduled interviews with the key healthcare providers responsible for HIV patient care in five regions of the country.ResultsThe total average cost of performing a viral load test in Nicaragua varied by region, ranging from US$99.01 to US$124.58, the majority of which was at the laboratory level: $88.73 to $97.15 per specimen, depending on batch size. The average cost to clinics at which specimens were collected ranged from $3.31 to $20.92, depending on the region. The average cost per patient for transportation, food, lodging and lost income ranged from $3.70 to $14.93.ConclusionsThe quantitative viral load test remains the single most expensive component of the process. For the patient, the distance of his or her residence from the specimen collection site is a large determinant of cost. Importantly, the efficiency of results reporting has a large impact on the cost per result delivered to the clinician and utility of the result for patient monitoring. Detailed cost analysis can identify opportunities for removing barriers to effective antiretroviral therapy monitoring programmes in limited‐resource countries with low HIV prevalence.
In: Journal of the International AIDS Society, Band 22, Heft S4
ISSN: 1758-2652
AbstractIntroductionUnderstanding the cost of strategies to reach and deliver pre‐exposure prophylaxis (PrEP) to priority populations is essential to assess the cost‐effectiveness and budget impact of HIV prevention programmes. Providing PrEP through maternal and child health and family planning clinics offers a promising strategy to reach women in high HIV burden settings. We estimated incremental costs and explored the cost drivers of integrating PrEP delivery into routine maternal and child health and family planning services in Kenya.MethodsWe conducted a costing study from the provider perspective within the PrEP Implementation for Young Women and Adolescents programme in western Kenya. We identified all within‐ and above‐facility activities supporting PrEP delivery and measured clinical service time using time‐and‐motion studies. We obtained input costs from programme budgets, expenditure records and staff interviews. We estimated changes in costs if creatinine testing were postponed from initiation to first follow‐up visit and if PrEP were prioritized to clients at high HIV risk using a behavioural risk assessment tool. We also projected costs under Ministry of Health (MOH) implementation assuming MOH salaries and programme supervision. We estimated annual numbers of PrEP visits from programme data abstracted from 16 facilities between November 2017 and June 2018. We report the cost per client‐month of PrEP dispensed in 2017 USD.ResultsFor an annual programme output of 24,005 screenings, 4198 PrEP initiations and 4427 follow‐up visits, the average cost per client‐month of PrEP dispensed in the study was $26.52. Personnel, drugs and laboratory tests comprised 43%, 25% and 14% of programme costs respectively. Postponing creatinine testing and prioritizing PrEP delivery to clients at high HIV risk reduced total programme costs by 8% and 14% respectively. In the MOH scenario assuming no changes in outputs, the projected cost per client‐month of PrEP dispensed decreased to $16.54 and total programme costs decreased by 38%.ConclusionsIncremental PrEP costs are sensitive to the service delivery strategy used to engage priority populations. Postponing creatinine testing and prioritizing PrEP delivery to clients at high HIV risk may reduce costs. Context‐specific cost data are crucial to assess the cost‐effectiveness and affordability of PrEP delivery models.